Lyndsey Elizabeth  Crennen net worth and biography

Lyndsey Crennen Biography and Net Worth

Lyndsey Crennen is the CAO of Mesa Laboratories.

What is Lyndsey Elizabeth Crennen's net worth?

The estimated net worth of Lyndsey Elizabeth Crennen is at least $188.02 thousand as of June 22nd, 2026. Crennen owns 2,020 shares of Mesa Laboratories stock worth more than $188,022 as of June 23rd. This net worth approximation does not reflect any other assets that Crennen may own. Learn More about Lyndsey Elizabeth Crennen's net worth.

How do I contact Lyndsey Elizabeth Crennen?

The corporate mailing address for Crennen and other Mesa Laboratories executives is 12100 W 6TH AVE, LAKEWOOD CO, 80228. Mesa Laboratories can also be reached via phone at (303) 987-8000 and via email at [email protected]. Learn More on Lyndsey Elizabeth Crennen's contact information.

Has Lyndsey Elizabeth Crennen been buying or selling shares of Mesa Laboratories?

Within the last three months, Lyndsey Elizabeth Crennen has sold $51,508.86 in Mesa Laboratories stock. Most recently, Lyndsey Elizabeth Crennen sold 442 shares of the business's stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a transaction totalling $39,559.00. Following the completion of the sale, the chief accounting officer now directly owns 2,020 shares of the company's stock, valued at $180,790. Learn More on Lyndsey Elizabeth Crennen's trading history.

Who are Mesa Laboratories' active insiders?

Mesa Laboratories' insider roster includes Brian Archbold (SVP), Mark Capone (Director), Lyndsey Crennen (CAO), Gregory DiNoia (SVP), Evan Guillemin (Director), David Kelly (Director), Shiraz Ladiwala (Director), Gary Owens (CEO), John Sakys (CFO), John Schmieder (Director), John Sullivan (Director), and R Tripeny (Director). Learn More on Mesa Laboratories' active insiders.

Are insiders buying or selling shares of Mesa Laboratories?

During the last twelve months, Mesa Laboratories insiders bought shares 3 times. They purchased a total of 6,116 shares worth more than $452,076.35. During the last twelve months, insiders at the medical instruments supplier sold shares 6 times. They sold a total of 8,277 shares worth more than $770,122.34. The most recent insider tranaction occured on June, 22nd when SVP Brian David Archbold sold 2,516 shares worth more than $225,182.00. Insiders at Mesa Laboratories own 4.9% of the company. Learn More about insider trades at Mesa Laboratories.

Information on this page was last updated on 6/22/2026.

Lyndsey Elizabeth Crennen Insider Trading History at Mesa Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/22/2026Sell442$89.50$39,559.002,020View SEC Filing Icon  
6/16/2026Sell118$101.27$11,949.861,473View SEC Filing Icon  
See Full Table

Lyndsey Elizabeth Crennen Buying and Selling Activity at Mesa Laboratories

This chart shows Lyndsey Elizabeth Crennen's buying and selling at Mesa Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mesa Laboratories Company Overview

Mesa Laboratories logo
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Read More

Today's Range

Now: $91.97
Low: $91.86
High: $96.69

50 Day Range

MA: $101.95
Low: $90.80
High: $109.13

2 Week Range

Now: $91.97
Low: $55.45
High: $113.99

Volume

208,462 shs

Average Volume

139,517 shs

Market Capitalization

$508.13 million

P/E Ratio

76.64

Dividend Yield

0.67%

Beta

0.94